We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Diane Reidy-Lagunes, MD, is the vice chair of the Regional Care Network at the Memorial Sloan Kettering (MSK) Cancer Center and past president of MSK’s medical staff. During the COVID crisis, she served as chief of clinical care in the COVID setting as part of the Hospital Incident Command System (HICS). read more
As a researcher, Dr Reidy-Lagunes focuses on developing methods to integrate molecular-based therapies into the treatment of neuroendocrine and endocrine tumours. She is a member of the National Cancer Institute Taskforce, and a member of the National Comprehensive Cancer Network Guidelines.
Dr Reidy-Lagunes is the recipient of several awards and honours, including the Paul Sherlock Resident Housestaff Teaching Award, Castle Connolly Top Doctors, and the American Cancer Society Mother of the Year Award. She is the creator and host of the podcast ‘Cancer Straight Talk from MSK’. In addition, she maintains a high-volume gastrointestinal oncology clinic.
Dr Diane Reidy-Lagunes discloses: Advisory board/panel fees from Advanced Accelerator Applications, Chiasma Inc., Ipsen and Novartis. Grants/research support fees from Ipsen, Merck and Novartis.
UCSF Health, San Francisco, CA, USA
Thomas Hope, MD, is the vice chair of clinical operations and strategy in the Department of Radiology, director of molecular therapy, and chief of nuclear medicine at the San Francisco VA Medical Center. He is also chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee. read more
In 2007, he received his medical degree from Stanford University School of Medicine and he completed a 1-year internship at Kaiser Permanente, San Francisco. From 2008 to 2012, Dr Hope completed a residency in diagnostic radiology at the University of California, San Francisco, followed by a clinical fellowship in body magnetic resonance imaging (MRI) and nuclear medicine from Stanford Medical Center in 2013. Dr Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumours. He led the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MRI with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI programme. Additionally, he leads the PRRT (peptide receptor radionuclide therapy) programme for neuroendocrine tumours and PSMA Radioligand Therapy at UCSF.
Dr Thomas Hope discloses Advisory board or panel fees from BlueEarth Diagnostics; Ipsen (relationship terminated). Consultancy fees from Bayer, Curium, ITM and RayzeBio. Grant/research support from Advanced Accelerator Applications, Bayer, Clovis Oncology and GE Healthcare; Advanced Accelerators Applications and Philips (relationships terminated). Stock/shareholder (self-managed) from RayzeBio.
Friedrich–Alexander University, Erlangen, Germany
Marianne Pavel, MD, is chair of the Division of Endocrinology at the Department of Medicine at Friedrich–Alexander University of Erlangen–Nürnberg, Erlangen, Germany, where she recently established another European Neuroendocrine Tumor Society (ENETS) Centre of Excellence. read more
Prof. Pavel received her medical degree in 1992 from the Georg–August University in Göttingen, Germany. In 1994, she completed her residency at the Friedrich–Alexander University of Erlangen–Nürnberg, Germany. Prof. Pavel became board certified as a specialist in internal medicine in 2000, and in endocrinology and diabetes in 2001. She was appointed as vice head of the Department of Endocrinology and Metabolism at the Friedrich–Alexander University in 2001.
From May 2007 to April 2017, Prof. Pavel was assistant director at the Charité University Hospital and the lead of the Neuroendocrine Tumour Section at the Department of Hepatology and Gastroenterology, Charité University Hospital, Campus Virchow–Klinikum in Berlin, Germany. She established a Clinical Trial Centre for NETs at the Charité University and conducted numerous clinical trials in NETs. In 2009, under her guidance, the NET Centre at the Charité University was certified as one of the first ENETS Centres of Excellence. Prof. Pavel was conferred a professorship for NET disease at the Charité University in January 2010. Since 2005, she has participated in ENETS activities and has been a member of the Executive Committee of ENETS since April 2014. Prof. Pavel was president of ENETS from April 2020 to April 2022.
Prof. Marianne Pavel discloses Advisory board or panel fees from Advanced Accelerators Applications, Esteve Pharmaceuticals (Riemser Pharma), Ipsen, Lilly, MSD, Novartis. Consultancy fees from Advanced Accelerators Applications, Boehringer Ingelheim, HUTCHMED, Ipsen.
Neuroendocrine Cancer UK, Leamington Spa, UK
Catherine Bouvier Ellis has dedicated the past 20 years of her career to improving the care and outcomes for patients with neuroendocrine cancer. As the first dedicated neuroendocrine cancer clinical nurse specialist (CNS) in the UK, and having set up the first UK-wide charity, she has experienced extensive challenges alongside a significant sense of achievement. read more
Her passion is to see the following eight strategic priorities be achieved in the field of neuroendocrine cancer:
Ms Catherine Bouvier Ellis discloses Grant/research support from Advanced Accelerator Applications and Ipsen.